Automated Aortic Stenosis Software (AutoAS)

Cardiology

Regulatory Status Disclosed

Overview

Automated Aortic Stenosis Software (AutoAS) is an ultrasound software application developed by GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC. It is designed to provide automated assessment of aortic stenosis, a common and serious heart valve condition. This tool aims to streamline and enhance the diagnostic workflow for cardiologists and sonographers by automating key measurements and calculations related to aortic valve function.

The software integrates with compatible ultrasound systems, leveraging AI and machine learning algorithms to analyze echocardiographic images. By automating the assessment process, AutoAS seeks to reduce inter-operator variability, improve efficiency, and potentially aid in earlier and more consistent identification of aortic stenosis severity. This can be particularly beneficial in busy clinical settings where rapid and reliable diagnostics are crucial.

For physicians, AutoAS offers a tool that can support clinical decision-making by providing objective and reproducible data on aortic valve hemodynamics. Its automated capabilities can free up valuable time, allowing clinicians to focus more on patient interaction and complex case interpretation. The integration into existing ultrasound platforms ensures a familiar user experience while enhancing diagnostic capabilities.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Automated aortic stenosis assessment
  • Echocardiographic image analysis
  • Reduced inter-operator variability
  • Integration with GE ultrasound systems
  • Support for clinical decision-making
  • Objective and reproducible data

Use Cases

  • Diagnosis of aortic stenosis
  • Monitoring aortic stenosis progression
  • Pre-operative assessment for valve replacement
  • Improving echocardiography workflow efficiency
  • Standardizing aortic valve measurements

What Physicians Need to Know

Echocardiography AI Features
AutoAS is an AI-based algorithm specifically designed to analyze ultrasound images of the heart to improve the diagnosis of aortic valve stenosis (AS). It aims to enhance the speed and accuracy of valve issue identification without using experimental devices. The software can automatically measure key AS parameters such as peak aortic velocity (Vmax), mean pressure gradient, and aortic valve area (AVA) using the continuity equation. It also assesses left ventricular function and flow, including LVEF and stroke volume index, to differentiate classical severe AS from paradoxical low-flow states. AutoAS is noted for being a fully automated, end-to-end system that requires zero human input from raw DICOM images to final severity classification, including view identification, Doppler tracing, and continuity equation calculation. It has demonstrated expert-level accuracy, with correlations of r = 0.76u20130.97 against expert sonographer measurements for key parameters, and r = 0.97 for Vmax.
AHA/ACC Guideline Alignment
While the search results do not explicitly state 'AutoAS' alignment with AHA/ACC guidelines, other AI echocardiography tools, such as Us2.ai, generate reports based on the latest guideline criteria. The ACC/AHA regularly publish guidelines for the diagnosis and management of aortic disease and valvular heart disease, which would be relevant for a tool like AutoAS.
Physician Tip

AutoAS appears to be a powerful tool for streamlining the diagnosis and grading of aortic stenosis through automated echocardiographic analysis. Physicians should leverage its ability to provide accurate, consistent measurements of key parameters like Vmax, mean gradient, and AVA, which can significantly reduce the time spent on manual measurements and improve workflow efficiency. The fully automated nature of the software, from raw images to severity classification, can help standardize assessments and potentially reduce inter-operator variability. While the tool focuses on aortic stenosis, the comprehensive assessment of LV function and flow can aid in differentiating complex cases. It's important to remember that while AI tools enhance efficiency and accuracy, human oversight remains crucial for validating AI-driven findings and ensuring the highest standards of patient care.

AutoAS is designed to analyze ultrasound images, suggesting integration with echocardiography systems. Other similar AI platforms for echocardiography integrate with standard ultrasound systems or Picture Archiving and Communication Systems (PACS) and can be deployed either on-premises or in the cloud. Such integrations allow for automated analysis and report generation directly from DICOM images, streamlining the workflow.

Details

Category Cardiology AI, Radiology & Imaging AI
Pricing Unknown — unknown
DeploymentCloud-based platforms are mentioned, such as HeartSciences' MyoVista Insights, which integrates with hospital EHR systems. Some solutions are designed for integration with existing ultrasound machines and electronic health records.
Mobile AppSome research indicates the feasibility of mobile solutions for detecting severe aortic valve stenosis using electronic stethoscopes and smartphones. Butterfly Network is also involved in research demonstrating the potential for machine learning models to support early detection of aortic stenosis using handheld ultrasound devices.
TrainingUnknown
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Cleared AI-estimated

Several companies have received FDA designations for their Aortic Stenosis AI software. iCardio.ai received FDA Breakthrough Device designation in February 2024 for its Aortic Stenosis screening tool and a 510(k) clearance for CardioVision™ in November 2025. AccurKardia's AVS screening software also received FDA Breakthrough Device Designation. HeartSciences Inc. announced FDA Breakthrough Device designation for its Aortic Stenosis ECG algorithm in June 2025. Automated Aortic Stenosis Software (AutoAS) from GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC, received FDA approval on March 27, 2026.

Integrations
EHR Not specified
Specialties Cardiology

Social Proof

Customersunknown
Notable
Echo IQ has deployed its EchoSolv AS software with the Mount Sinai Health System in New York. Viz.aia company that partners with iCardio.aiworks with over 1500 hospitals and health systems in the U.S. and Europe.

Support & Reliability

Training ProvidedUnknown

What the Web Says

Automated Aortic Stenosis Software (AutoAS) refers to AI-powered tools designed to assist clinicians in detecting, grading, and managing aortic stenosis (AS) through the analysis of medical images like echocardiograms and CT scans. These technologies aim to improve diagnostic accuracy, streamline workflows, and enable earlier intervention for this serious heart condition.

Overall: Positive

Strengths

  • Improved diagnostic accuracy and reproducibility across different readers and sites.
  • Earlier detection of aortic stenosis, potentially years before traditional methods.
  • Reduced interscan variability in measurements.
  • Automated measurements of key parameters, saving time for clinicians.
  • Potential for expanded screening and risk assessment due to the widespread availability and lower cost of some input data (e.g., ECGs).
  • Can identify patients at risk even before structural abnormalities are visible on conventional imaging.

Limitations

  • Some studies are still in the trial phase, focusing on development and validation rather than widespread clinical adoption.
  • Reliance on existing ultrasound machines for image capture, not new treatment devices.
  • Potential for user error in manual measurements, which AI aims to mitigate.
  • The technology is still emerging, with ongoing research and development.
  • Lack of extensive real-world physician reviews outside of research contexts.
  • No specific mentions of reviews from G2 or Capterra, indicating it might not be a widely adopted commercial product with public user reviews on those platforms yet.

Based on reviews from: RadAI Slice, WithPower (Clinical Trial), Artificial Intelligence to Assist Physicians in Identifying Patients with Severe Aortic Stenosis (Journal Article), Aortic Stenosis Detection and Classification with an AI Echo Solution (Us2.ai), Automated Detection of Aortic Stenosis using Machine Learning - iCardio.ai, Fully Automated Artificial Intelligence Assessment of Aortic Stenosis by Echocardiography - The Valve Club, A fully automated artificial intelligence-driven software for planning of transcatheter aortic valve replacement - PubMed, Reddit (r/Scholar, r/valvereplacement), Artificial Intelligence in the Screening, Diagnosis, and Management of Aortic Stenosis - PMC, Prediction of Aortic Stenosis Progression Using Artificial Intelligence: A Machine Learning Model - PMC, Study Shows AI-Enabled ECG Can Detect Aortic Stenosis Years Before Valve Replacement (Diagnostic and Interventional Cardiology), Aortic Stenosis Detection with AI Echo - Us2.ai, AI-enabled ECG tool detects aortic stenosis years before intervention, study finds (Healio), Imaging to Intervention: Automating Aortic Stenosis Detection in the EHR | UC Tech 2025, Automated detection of severe aortic stenosis using single-view echocardiography: A self-supervised ensemble learning approach | medRxiv, Emerging ECG-Based AI Screening Software for Aortic Valve Stenosis Gets FDA's Breakthrough Device Designation | Diagnostic Imaging

Last updated: 2026-08-19

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate Automated Aortic Stenosis Software (AutoAS)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

FDA
Automated Aortic Stenosis Software (AutoAS) (K254161) u2014 FDA
This is a 510(k) Premarket Notification for Automated Aortic Stenosis Software (AutoAS) by GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC, indicating regulatory clearance for the device.
2026-04
FDA
Breakthrough Devices Program | FDA
The FDA lists Automated Aortic Stenosis Software (AutoAS) (K254161) from GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC as a device that has received marketing authorization under the Breakthrough Devices Program as of March 31, 2026.
2026-06
FDA.report
Automated Aortic Stenosis A-1.0 GUDID Device - FDA.report
This entry details the Automated Aortic Stenosis Software (AutoAS) with its decision date of March 27, 2026, and identifies it as an individual software program for image processing and analysis capabilities for diagnostic ultrasound systems.
2026-05
RadAI Slice
Automated Aortic Stenosis Software (AutoAS) | FDA Radiology AI Device - RadAI Slice
Automated Aortic Stenosis Software (AutoAS) is described as a computer-assisted diagnostic tool designed to help clinicians analyze medical images and identify lesions related to aortic stenosis assessment.
unknown
FDA
Artificial Intelligence-Enabled Medical Devices - FDA
The FDA includes Automated Aortic Stenosis Software (AutoAS) by GE Medical Systems Ultrasound & Primary Care Diagnostics, LLC in its list of Artificial Intelligence-Enabled Medical Devices, with a decision date of March 27, 2026.
2026-03
The Workup | Matt Kaili, MD | Substack
Case File: The death of eyeballing it in POCUS? - The Workup | Matt Kaili, MD | Substack
This article mentions GE's clearance of Automated Aortic Stenosis software (AutoAS, K254161) on March 27, highlighting a trend of automated quantification methods in cardiac echo.
2026-05
LinkedIn
FDA Breakthrough Device Aortic Stenosis Screening Market : Global ...
This LinkedIn article references the 510(k) premarket notification for Automated Aortic Stenosis Software (AutoAS), K254161, in the context of the FDA Breakthrough Device Aortic Stenosis Screening Market.
2026-07
X-ray Interpreter
Vivid iq | FDA Radiology AI Device - X-ray Interpreter
This page, while primarily about Vivid iq, lists Automated Aortic Stenosis Software (AutoAS) as another device from GE Medical Systems Ultrasound & Primary Care Diagnostics LLC, with a 510K clearance in 2026.
unknown

Videos

Product demos, reviews, and walkthroughs for Automated Aortic Stenosis Software (AutoAS).

Loading videos...

View all on YouTube

Frequently Asked Questions

AutoAS leverages AI to analyze medical images, particularly echocardiograms, to identify and grade aortic stenosis (AS) severity. It automates measurements of key parameters like peak aortic velocity (Vmax), mean pressure gradient, and aortic valve area, which can lead to more consistent and accurate diagnoses compared to manual methods. This automation can significantly reduce the time required for measurements and report creation, streamlining the echocardiographic assessment workflow and potentially allowing for earlier intervention and personalized treatment plans.
The use of autonomous AI systems in medicine, including those like AutoAS, raises concerns about liability, regulation, and costs. While AI can assist clinicians, the question of who holds accountability for decisions remains, especially as AI systems become more sophisticated. Regulatory bodies like the FDA are working to ensure transparency, evaluation, and real-world monitoring of AI systems in healthcare. Physicians may be favored in malpractice cases if they follow rigorously validated AI recommendations, but AI developers may face liability for negligent design or implementation.
While AI-powered tools offer significant advantages, limitations exist. The dynamic learning nature of AI can complicate determining software error rates at a specific time, and the technical complexities may require expertise from both developers and physicians. AI models, including large language models, can sometimes generate misunderstandings or misinformation due to a lack of real-time updates or context sensitivity. Additionally, the performance of automated algorithms can be influenced by confounders and artifacts, and in cases of fair or poor image quality, AI may require more corrections and extended measurement time.
While the specific 'AutoAS' name might refer to a particular product or a general concept, other AI-enabled tools and traditional methods exist for aortic stenosis assessment. For example, AccurKardia's AI-enabled electrocardiogram technology can detect AS earlier, and other AI solutions like Us2.ai offer fully automated echocardiogram analysis for AS grading. Traditional methods primarily rely on expert interpretation of echocardiograms, which can be user-dependent and may have higher variability.
Specific pricing for 'Automated Aortic Stenosis Software (AutoAS)' is not readily available in the provided search results. However, general AI software pricing models vary. Some software, like fleet management tools, offer monthly or annual subscriptions with volume discounts. Other software, such as Autocase, might offer annual subscriptions per user or project-based fees. The impact on a cardiology practice would depend on the vendor's pricing structure, potential integration costs, and whether the cost savings from increased efficiency and improved diagnostic accuracy outweigh the investment.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-08-19 | First Added: 2026-08-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.